The Journal of Experimental Medicine
VeriKine-HS Human IFN-Beta
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

Published online 9 October 2006 doi:10.1084/jem.20311iti1
Rockefeller University Press, 0022-1007 $8.00
JEM, Volume 203, Number 11, 2393-2393
This Article
Right arrow Full Text (PDF, 1024K)
Right arrow PPT slides of all figures
Right arrow Alert me when this article is cited
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Alert me to new content in the JEM
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Williams, R.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Williams, R.
Related Collections
Right arrowRelated Article
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

IN THIS ISSUE

Curtailing infection

Figure 1
Mice with suppressed IL-10 action (right) eradicate persistent viral infection and improve their health.

Certain crafty viruses can cause the host's immune system to suppress itself, and thereby establish persistent chronic infection. But Ejrnaes et al. (page 2461) and Brooks et al. (Nat. Med. doi:10.1038/nm1492) have now found that suppressing the suppressor, which they show is the cytokine IL-10, can fight persistent infection.

IL-10 is known to exert a suppressive effect on cells of the immune system, including T cells and antigen-presenting cells, and elevated levels of IL-10 have been observed during persistent infection with hepatitis C virus, human immunodeficiency virus, and Epstein-Barr virus.

Now, both teams have observed that mice lacking IL-10 are resistant to persistent infection with lymphocytic choriomeningitis virus (LCMV). They also show that normal mice infected with LCMV have increased IL-10 production and decreased numbers of virus-killing CD8+ T cells. Ejrnaes et al. show that treating LCMV-infected mice with antibody that blocks the IL-10 receptor restored these antiviral CD8+ T cells and resulted in low or undetectable viral load, less weight loss and healthier coats. Importantly, the same reversal of symptoms and eradication of virus was achieved if treatment was administered later in infection.

Blocking the action of IL-10 might, therefore, be a potential therapy for human cases of persistent viral infection. Prolonged treatment with a potent stimulator of the immune system, however, might lead to undesirable autoimmune conditions, explains Matthias von Herrath, who led the study published here. His team is thus looking into the use of shorter and lower dose IL-10 treatments in combination with vaccines against virus-specific antigens. Formula



Ruth Williams

ruth.williams{at}rockefeller.edu


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?

Related Article

Resolution of a chronic viral infection after interleukin-10 receptor blockade
Mette Ejrnaes, Christophe M. Filippi, Marianne M. Martinic, Eleanor M. Ling, Lisa M. Togher, Shane Crotty, and Matthias G. von Herrath
J. Exp. Med. 2006 203: 2461-2472. [Abstract] [Full Text] [PDF]




This Article
Right arrow Full Text (PDF, 1024K)
Right arrow PPT slides of all figures
Right arrow Alert me when this article is cited
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Alert me to new content in the JEM
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Williams, R.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Williams, R.
Related Collections
Right arrowRelated Article
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?


  Home | Help | Feedback | Subscriptions | Archive | Search
TABLE OF CONTENTS